Respiratory Syncytial Virus Pre-Fusion Glycoprotein F

Summary

Respiratory Syncytial Virus Pre-Fusion Glycoprotein F (CHEMBL6068489) is an approved vaccine component; indicated across 2 conditions including respiratory syncytial virus infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 2 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068489
Name	Respiratory Syncytial Virus Pre-Fusion Glycoprotein F
Type	Vaccine component
Max phase	4

Also known as: Abrysvo, Arexvy

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
respiratory syncytial virus infectious disease	4	MONDO:0001577	EFO:1001413

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
Not specified	5
PHASE1	3
PHASE4	2
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05170399	PHASE4	RECRUITING	Vaccine Responses in Patients With B Cell Malignancies
NCT06551506	PHASE4	COMPLETED	The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
NCT07041190	PHASE3	NOT_YET_RECRUITING	Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.
NCT07232706	PHASE3	RECRUITING	Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination
NCT07050732	PHASE2	RECRUITING	Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
NCT06556147	PHASE1	ACTIVE_NOT_RECRUITING	A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults
NCT06843317	PHASE1	RECRUITING	Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
NCT06194318	PHASE1	COMPLETED	First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
NCT06647654	Not specified	ACTIVE_NOT_RECRUITING	Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy
NCT06813872	Not specified	ACTIVE_NOT_RECRUITING	Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
NCT07122661	Not specified	ACTIVE_NOT_RECRUITING	STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)
NCT07235397	Not specified	NOT_YET_RECRUITING	Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset
NCT07249320	Not specified	ACTIVE_NOT_RECRUITING	Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).